| Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic SA Mendonça, R Lorincz, P Boucher, DT Curiel npj Vaccines 6 (1), 97, 2021 | 237 | 2021 |
| Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors P Boucher, X Cui, DT Curiel Journal of Controlled Release 327, 788-800, 2020 | 37 | 2020 |
| Vector strategies to actualize B cell–based gene therapies AM Jeske, P Boucher, DT Curiel, JE Voss The Journal of Immunology 207 (3), 755-764, 2021 | 6 | 2021 |
| A Novel Piggyback Strategy for mRNA Delivery Exploiting Adenovirus Entry Biology M Lee, PJ Rice-Boucher, LT Collins, E Wagner, L Aulisa, J Hughes, ... Viruses 14 (10), 2169, 2022 | 3 | 2022 |
| Adenoviral vectors infect B lymphocytes in vivo PJ Rice-Boucher, SA Mendonça, AB Alvarez, AJ Sturtz, R Lorincz, ... Molecular Therapy 31 (9), 2600-2611, 2023 | 2 | 2023 |
| PPRX-1701, a nanoparticle formulation of 6′-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models M Zdioruk, JL Jimenez-Macias, MO Nowicki, KE Manz, KD Pennell, ... Cell Reports Medicine 4 (5), 2023 | 2 | 2023 |
| Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation K Geng, PJ Rice-Boucher, EA Kashentseva, IP Dmitriev, ZH Lu, ... Viruses 15 (11), 2277, 2023 | 1 | 2023 |
| STABILIZATION OF RNA FOR EXOGENOUS RNAi AGRICULTURAL APPLICATIONS AND FORMULATIONS W Stewart, L Aulisa, D Villiard, J Gillian, K Owens, N Dodwadkar, ... US Patent App. US20230106660A1, 2023 | | 2023 |
| Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same B Wu, P Boucher US Patent App. US20230100193A1, 2023 | | 2023 |
| PPRX-1701, a deliverable nanoparticle formulation of 6-bromo-acetoxime, blocks tumoral IDO1 expression and shows efficacy in immunocompetent murine glioblastoma models M Zdioruk, M Nowicki, B Wu, P Boucher, Y Takeda, W Li, EA Chiocca, ... Cancer Research 82 (12_Supplement), 4235-4235, 2022 | | 2022 |
| ENGINEERED ADENOVIRAL VECTORS EFFICIENTLY TRANSDUCE PRIMARY MURINE LYMPHOCYTES IN VITRO AND IN VIVO DTC PJ Rice-Boucher, SA Mendonca International Conference on Lymphocyte Engineering, 2022 | | 2022 |
| PPRX-1701, a Nanoparticle Formulation of 6’-Bromoindirubin Acetoxime, Improves Delivery and Shows Efficacy in Immune Competent Preclinical GBM Models M Zdioruk, OM Nowicki, M Koch, T Finkelberg, B Wu, P Boucher, ... Improves Delivery and Shows Efficacy in Immune Competent Preclinical GBM Models, 0 | | |
David T. CurielWashington University School of Medicine在 wustl.edu 的电子邮件经过验证
